See associations below
Fluorescent in situ Hybridization, FISH
| Test Code | Description |
|---|---|
| F 4Q12 | FIP1L1/PDGFRA 4q12 rearrangement |
| F 7q | Deletion 7q22 |
| F ALK, FP ALK | ALK 2p23 rearrangment |
| F AML ETO | AML1/ETO, t(8;21) |
| FP ANEU* | Molar Pregnancy Panel +13, +18, +21,X,Y |
| F API MALT*, FP API MALT* | API2/MALT1 t(11;18)(q22;q21) |
| F AS* | Angelman Syndrome deletion 15q11-13 |
| F ATM | ATM/CEP 11 deletion 11q22.3 |
| F BCL1, FP BCL1 | BCL1(CCND1)/IGH t(11;14) |
| F BCL2, FP BCL2 | BCL2; IGH/BCL2 t(14;18) |
| F BCL6, FP BCL6 | BCL6 3q27 rearrangement |
| F BCR ABL | BCR/ABL1 t(9;22) |
| F BURKITT, FP BURKITT | Burkitt/“Double Hit” Large B-cell Lymphoma Panel |
| F CBFB | CBFB t(16;16) and inv(16) |
| F CLL | Chronic Lymphocytic Leukemia (CLL) Panel |
| F CMYC, FP CMYC | CMYC 8q24 rearrangement |
| F D1314 | Deletion 13q14.3 |
| F D20 | Deletion 20q12 |
| F Del5p* | Cri-du-Chat / SOTOS Syndrome |
| FP EGFR* | EGFR amplification (7p11.2) |
| F EGR1 | EGR1 5q delection, monosomy 5 |
| F FGFR3 | IGH/FGFR3 t(4;14) |
| F GLI*, FP GLI* | Oligodendroglioma, deletion 1p36, 19q13 |
| FP HER2 | HER2/neu breast |
| FP HER2 GA | HER2/neu gastric |
| F IGH*, FP IGH* | IGH 14q32 rearrangement |
| F IGH MAF | IGH/MAF t(14;16) |
| F IGH MALT1, FP IGH MALT1 | IGH/MALT1 (t(14;18) |
| F IGH MYC*, FP IGH MYC* | IGH/MYC t(8;14) |
| F KAL* | Kallmann Syndrome deletion Xp22.3 |
| F LIS* | Miller-Dieker Syndrome / Lissencephaly deletion 17p13.3 |
| F MALT, FP MALT | MALT1 18q21 rearrangement |
| F MDS | Myelodsyplasia Panel |
| F MLL | MLL 11q23 rearrangement |
| F MM | Plasma Cell Neoplasms |
| F MPD | Myeloproliferative Neoplasms Panel |
| F MYB | MYB 6q deletion |
| F P53 | TP53 deletion 17p13 |
| F PDGFRB | PDGRRB rearrangement |
| F PML RARA | PML/RARA t(15;17) |
| F PMS* | Phelan-McDermid Syndrome, deletion 22q13 |
| F PWS* | Prader-Willi Syndrome deletion 15q11 |
| FP ROS1 | ROS1 6q22.1 rearrangement |
| F SRY* | SRY region, Yp11.3/Xp11.1q11.1 |
| F STS* | Steroid Sulfatase Deficiency deletion Xp22, x-linked ichthyosis |
| F SYT* | SYT 18q11.2 |
| F TEL AML1* | TEL/AML1 t(12;21) |
| F T5T9T15 | Trisomy 5, 9 and 15 |
| F T8 | Trisomy 8 |
| F T12 | Trisomy 12 |
| F T21* | Trisomy 21 |
| F URO | Bladder cancer +3, +7, +17, 9p21- |
| F WH* | Wolf-Hirschhorn Syndrome deletion 4p16.3 |
| F WIL* | Williams Syndrome deletion 7q11.2 |
Fluorescence in situ Hybridization (FISH)
*Performed by affiliate laboratory
FP = stipulates FFPE or paraffin embedded tissue acceptable specimen type
3 -5 days
F
5mL peripheral blood in sodium heparin
3mL bone marrow in sodium heparin
Fixed cytogenetically prepared cells in sterile centrifuge tube with pellet visible in 3:1, Methanol:Acetic Acid
FP
FFPE tissue is acceptable for FISH analysis. Preferred fixative is 10% neutral buffered formalin. Tissues preserved in B5 fixative or decalcified are usually not suitable for FISH. Tumor sections cut 3-5 µm thick and mounted on positively charged organosilane coated (silanized) slides work well. Request several unstained sections (two for each probe) and one H&E stained slide
4°C to 25°C during transit, but specimens may be transported on refrigerated gel packs. Do not allow the gel pack to come in contact with the specimen. Do not freeze. Extreme temperatures should be avoided.
Clotted specimen; Specimen exposed to extreme temperature; Anticoagulant toxic to cells; Insufficient number of cells; Improper fixative
See report.
Fluorescence in situ Hybridization (FISH) performed on interphase cells.